Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the DigitalDiagnost C90, its newest premium digital radiography system. Designed to increase patient throughput and decrease the time to diagnosis, the Philips DigitalDiagnost C90 offers healthcare organizations a flexible and customizable imaging solution that helps to improve workflow and clinical outcomes, while adding economic value.
X-ray is often the start of a patient’s care journey and plays a critical role in supporting clinical care decisions from that point forward – making high quality imaging essential. As the industry’s first radiography unit with a live camera image directly displayed at the tube head, DigitalDiagnost provides a clear view of the anatomical area being scanned during the patient positioning process – improving workflow so that clinicians can be confident that the right area is captured with a low X-ray dose exposure. With Philips’ UNIQUE 2 image processing and Bone Suppression software [1], radiologists can process clearer images for a more confident diagnosis with a lower chance of a costly and timely rescan.
DigitalDiagnost C90 also incorporates the Philips Eleva user interface, a common platform across a range of Philips digital radiography systems that enables a smooth and efficient patient-focused workflow. This common user interface is now extended to the Eleva Tube Head, speeding up workflow by over 17% per examination [2]. Its touch screen display transfers operation into the examination room to allow for more time with the patient. DigitalDiagnost also helps contribute to a lower cost of care, with flexible room configuration options and SkyPlate sharing available among all Philips premium digital radiography systems.
